Stock Research for attbf

attbf

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

attbf Stock Chart & Research Data

The attbf chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the attbf chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


attbf Due diligence Resources & Stock Charts

The attbf stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View attbf Detailed Price Forecast - CNN Money CNN View attbf Detailed Summary - Google Finance
Yahoo View attbf Detailed Summary - Yahoo! Finance Zacks View attbf Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View attbf Trends & Analysis - Trade-Ideas Barrons View attbf Major Holders - Barrons
NASDAQ View attbf Call Transcripts - NASDAQ Seeking View attbf Breaking News & Analysis - Seeking Alpha
Spotlight View attbf Annual Report - CompanySpotlight.com OTC Report View attbf OTC Short Report - OTCShortReport.com
TradeKing View attbf Fundamentals - TradeKing Charts View attbf SEC Filings - Bar Chart
WSJ View Historical Prices for attbf - The WSJ Morningstar View Performance/Total Return for attbf - Morningstar
MarketWatch View the Analyst Estimates for attbf - MarketWatch CNBC View the Earnings History for attbf - CNBC
StockMarketWatch View the attbf Earnings - StockMarketWatch MacroAxis View attbf Buy or Sell Recommendations - MacroAxis
Bullish View the attbf Bullish Patterns - American Bulls Short Pains View attbf Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View attbf Stock Mentions - StockTwits PennyStocks View attbf Stock Mentions - PennyStockTweets
Twitter View attbf Stock Mentions - Twitter Invest Hub View attbf Investment Forum News - Investor Hub
Yahoo View attbf Stock Mentions - Yahoo! Message Board Seeking Alpha View attbf Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for attbf - SECform4.com Insider Cow View Insider Transactions for attbf - Insider Cow
CNBC View attbf Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for attbf - OTC Markets
Yahoo View Insider Transactions for attbf - Yahoo! Finance NASDAQ View Institutional Holdings for attbf - NASDAQ


Stock Charts

FinViz View attbf Stock Insight & Charts - FinViz.com StockCharts View attbf Investment Charts - StockCharts.com
BarChart View attbf Stock Overview & Charts - BarChart Trading View View attbf User Generated Charts - Trading View




Latest Financial News for attbf


Abattis Announces Acquisition of European Nutraceutical Company and Provides Corporate Updates
Posted on Tuesday April 02, 2019

VANCOUVER, British Columbia, April 2, 2019 /PRNewswire/ -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (ATT.CN) (ATTBF) is pleased to announce that its wholly-owned subsidiary, 1185277 B.C. Ltd. (the "Acquisition Subsidiary"), has entered into a share purchase agreement (the "Agreement") to acquire (the "Acquisition") Pro Natura BV ("Pro Natura"), a privately held nutraceutical company based in Oisterwijk, Netherlands. Pro Natura has over 30 years of operations and sales experience in Europe, with over 100 products that have been marketed to both long-term repeat customers and new large groups of distributors. Pro Natura has been supported by a seasoned management team that still includes its original founder and has historically boasted €10M+ in per annum sales.


Abattis Announces Resignation of Directors
Posted on Saturday March 09, 2019

Vancouver, British Columbia--(Newsfile Corp. - March 9, 2019) - Abattis Bioceuticals Corp (CSE: ATT) (OTC Pink: ATTBF) (the "Company" or "Abattis") announces that, effective February 20, 2019 and March 6, 2019, both Wolfgang Richter and James Irving have respectively resigned as directors of the Company.The Company thanks both Mr. Richter and Mr. Irving for their service and wishes each all the best in their future endeavors.About Abattis Bioceuticals Corp.Abattis is positioned to be ...


Abattis Provides Update on Conference Call
Posted on Wednesday February 27, 2019

Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) provides the following update on the Company’s recent trading halt and upcoming conference call with Company management that was previously set for March 1, 2019. Further to the Company’s news release dated February 18, 2019, trading of the Company’s common shares continues to be halted on the Canadian Securities Exchange until the Company files its financial statements for the year ended September 30, 2018 (the “Financials”).


Abattis Provides Update on Trading Halt and Announces Management Conference Call
Posted on Monday February 18, 2019

Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to provide the following update on the Company’s recent trading halt and upcoming conference call with Company management set for March 1, 2019. On February 4, 2019, the trading of the Company’s common shares was halted due to the Company’s failure to file its year-end financial statements within the 90 day filing deadline required under National Instrument 51-102 – Continuous Disclosure Requirements.  The Company is still undergoing its year-end financial statement audit and believes it will have them filed in the coming week.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.